Search

Your search keyword '"Avouac, Jérôme"' showing total 727 results
Start Over Author "Avouac, Jérôme"
727 results on '"Avouac, Jérôme"'

3. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages

Author

Driouich, Jean-Sélim, Cochin, Maxime, Lingas, Guillaume, Luciani, Léa, Baronti, Cécile, Bernadin, Ornéllie, Gilles, Magali, Villarroel, Paola Mariela Saba, Moureau, Grégory, Petit, Paul-Rémi, Dupont, Axelle, Izopet, Jacques, Kamar, Nassim, Autran, Brigitte, Paintaud, Gilles, Caillard, Sophie, le Bourgeois, Amandine, Richez, Christophe, Couzi, Lionel, Xhaard, Aliénor, Marjanovic, Zora, Avouac, Jerome, Jacquet, Caroline, Anglicheau, Dany, Cheminant, Morgane, Nguyen, Stéphanie, Terrier, Benjamin, Gottenberg, Jacques Eric, Besson, Caroline, Letrou, Sophie, Tine, Josephine, Basilua, Joe Miantezila, Angoulvant, Denis, Tardivon, Coralie, Blancho, Gilles, Martin-Blondel, Guillaume, Yazdanpanah, Yazdan, Mentré, France, Lévy, Vincent, Touret, Franck, Guedj, Jérémie, de Lamballerie, Xavier, and Nougairède, Antoine

Published
2024
Full Text
View/download PDF

8. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, Jeffrey A, Wallace, Zachary S, Seet, Andrea M, Gianfrancesco, Milena A, Izadi, Zara, Hyrich, Kimme L, Strangfeld, Anja, Gossec, Laure, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Wise, Leanna, Gilbert, Emily L, Duarte-García, Ali, Valenzuela-Almada, Maria O, Pons-Estel, Guillermo J, Isnardi, Carolina A, Berbotto, Guillermo A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Kearsley-Fleet, Lianne, Schäfer, Martin, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Tidblad, Liselotte, Scirè, Carlo Alberto, Raffeiner, Bernd, Thomas, Thierry, Flipo, René-Marc, Avouac, Jérôme, Seror, Raphaèle, Bernardes, Miguel, Cunha, Maria Margarida, Hasseli, Rebecca, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Specker, Christof, de Souza, Viviane Angelina, da Mota, Licia Maria Henrique, Gomides, Ana Paula Monteiro, Dieudé, Philippe, Nikiphorou, Elena, Kronzer, Vanessa L, Singh, Namrata, Ugarte-Gil, Manuel F, Wallace, Beth, Akpabio, Akpabio, Thomas, Ranjeny, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Yazdany, Jinoos, Dahou, Brahim, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María Haye, Maldonado, Federico Nicolas, Reyes, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Tessel, Ivana Romina, Alamino, Rodolfo Perez, Werner, Marina Laura, Ornella, Sofía, and Casalla, Luciana

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Infectious Diseases, Rheumatoid Arthritis, Coronaviruses, Autoimmune Disease, Arthritis, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, COVID-19, Female, Humans, Male, Middle Aged, Registries, SARS-CoV-2, Severity of Illness Index, COVID-19 Global Rheumatology Alliance, Covid-19, abatacept, rheumatoid arthritis, rituximab, tumour necrosis factor inhibitors, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

9. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, Anja, Schäfer, Martin, Gianfrancesco, Milena A, Lawson-Tovey, Saskia, Liew, Jean W, Ljung, Lotta, Mateus, Elsa F, Richez, Christophe, Santos, Maria J, Schmajuk, Gabriela, Scirè, Carlo A, Sirotich, Emily, Sparks, Jeffrey A, Sufka, Paul, Thomas, Thierry, Trupin, Laura, Wallace, Zachary S, Al-Adely, Sarah, Bachiller-Corral, Javier, Bhana, Suleman, Cacoub, Patrice, Carmona, Loreto, Costello, Ruth, Costello, Wendy, Gossec, Laure, Grainger, Rebecca, Hachulla, Eric, Hasseli, Rebecca, Hausmann, Jonathan S, Hyrich, Kimme L, Izadi, Zara, Jacobsohn, Lindsay, Katz, Patricia, Kearsley-Fleet, Lianne, Robinson, Philip C, Yazdany, Jinoos, Machado, Pedro M, Dahou, Brahim, Pinheiro, Marcelo, Ribeiro, Francinne M, Chassin-Trubert, Anne-Marie, Ibáñez, Sebastián, Dong, Lingli, Cajas, Lui, Hamoud, Hesham, Avouac, Jérôme, Belin, Véronique, Borie, Raphaël, Chazerain, Pascal, Chevalier, Xavier, Claudepierre, Pascal, Clavel, Gaëlle, Colette-Cedoz, Marie-Eve, Combe, Bernard, Constant, Elodie, Costedoat-Chalumeau, Nathalie, Desmurs, Marie, Devauchelle-Pensec, Valérie, Devaux, Mathilde, Dhote, Robin, Dieudonné, Yannick, Domont, Fanny, Duret, Pierre-Marie, Ebbo, Mikaël, Ebstein, Esther, Mahou, Soumaya El, Fautrel, Bruno, Felten, Renaud, Flipo, René-Marc, Foltz, Violaine, Froissart, Antoine, Galland, Joris, Gaud-Listrat, Véronique, Georgin-Lavialle, Sophie, Giraud-Morelet, Aude, Quitrec, Jeanine S Giraudet-Le, Goupille, Philippe, Govindaraju-Audouard, Sophie, Grados, Franck, Guillaume-Czitrom, Séverine, Hermet, Marion, Hittinger-Roux, Ambre, Hudry, Christophe, Kone-Paut, Isabelle, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambrecht, Isabelle, Langlois, Vincent, Larbre, Jean-Paul, Ledoult, Emmanuel, Leroux, Christophe, Liote, Frédéric, Maria, Alexandre TJ, Marotte, Hubert, Mekinian, Arsène, Melki, Isabelle, Messer, Laurent, Michel, Catherine, and Morel, Gauthier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Autoimmune Disease, Arthritis, Coronaviruses, Emerging Infectious Diseases, Cardiovascular, Inflammatory and immune system, Good Health and Well Being, Aged, Antirheumatic Agents, COVID-19, Comorbidity, Female, Global Health, Glucocorticoids, Humans, Male, Middle Aged, Odds Ratio, Registries, Rheumatic Diseases, Rheumatology, SARS-CoV-2, antirheumatic agents, autoimmune diseases, epidemiology, glucocorticoids, outcome assessment, health care, COVID-19 Global Rheumatology Alliance, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo determine factors associated with COVID-19-related death in people with rheumatic diseases.MethodsPhysician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.ResultsOf 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.ConclusionAmong people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

Published
2021

11. The phenotype of mixed connective tissue disease patients having associated interstitial lung disease

Author

Boleto, Gonçalo, Reiseter, Silje, Hoffmann-Vold, Anna-Maria, Mirouse, Adrien, Cacoub, Patrice, Matucci-Cerinic, Marco, Silvério-António, Manuel, Fonseca, Joao Eurico, Duarte, Ana Catarina, Pestana Lopes, Jorge, Riccieri, Valeria, Lescoat, Alain, Le Tallec, Erwan, Castellví Barranco, Ivan, Tandaipan, Jose Luis, Airó, Paolo, Kuwana, Masataka, Kavosi, Hoda, Avouac, Jérôme, and Allanore, Yannick

Published
2023
Full Text
View/download PDF

15. COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection

Author

Comarmond, Cloé, Drumez, Elodie, Labreuche, Julien, Hachulla, Eric, Thomas, Thierry, Flipo, René-Marc, Seror, Raphaëlle, Avouac, Jérôme, Balandraud, Nathalie, Desbarbieux, Renaud, Felten, Renaud, Gilson, Mélanie, Guyot, Marie-Hélène, Hittinger-Roux, Ambre, Pham, Thao, Renard, Myriam, Roux, Nicolas, Sobanski, Vincent, Tournadre, Anne, Richez, Christophe, and Cacoub, Patrice

Published
2023
Full Text
View/download PDF

17. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Matucci Cerinic, Marco, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Kowal Bielecka, Otylia, Cutolo, Maurizio, Cuomo, Giovanna, Kedor, Claudia, Rednic, Simona, Avouac, Jérome, Vlachoyiannopoulos, P., Montecucco, C., Stork, Jiri, Inanc, Murat, Carreira, Patricia E., Novak, Srdan, Czirják, László, Iudici, Michele, Kucharz, Eugene J., Zanatta, Elisabetta, Perdan-Pirkmajer, Katja, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstrand, Roger, Radic, Mislav, Braun-Moscovici, Yolanda, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Vonk, Madelon, Damjanov, Nemanja, Henes, Jörg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Kohm, Michaela, Foeldvari, Ivan, Bajocchi, Gianluigi, Salvador, Maria João, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Ananieva, Lidia P., Herrick, Ariane, Müller-Ladner, Ulf, De Palma, Raffaele, Engelhart, Merete, Szücs, Gabriela, Sobrino Grande, Cristina, Midtvedt, Øyvind, Launay, David, Riccieri, Valeria, Ionescu, Ruxandra Maria, Sha, Ami, Gheorghiu, Ana Maria, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Ullman, Susanne, Alberto von Mühlen, Carlos, Pozzi, Maria Rosa, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Alegre-Sancho, Juan Jose, Herrmann, Kristine, De Langhe, Ellen, Anic, Branimir, Üprus, Maria, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Busquets, Joanna, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Sampaio-Barros, Percival D., Stamp, Lisa, Solanki, Kamal, Veale, Douglas, Loyo, Esthela, Li, Mengtao, Abdel Atty Mohamed, Walid Ahmed, Gigante, Antonietta, Oksel, Fahrettin, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Abignano, Giuseppina, Seskute, Goda, Saketkoo, Lesley Ann, Kerzberg, Eduardo, Bianchi, Washington, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, François, Marcoccia, Antonella, Kahl, Sarah, Hsu, Ivien M., Martin, Thierry, Moiseev, Sergey, Chung, Lorinda S., Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Sommerlatte, Sabine, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Francis, Belloli, Laura, Sfikakis, Petros, Markus, Juliana, Feldman, Gary R, Ramazan, Ana-Maria, Scherer, H.U., Truchetet, Marie-Elise, Lescoat, Alain, Dagna, Lorenzo, van Laar, J.M., Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, Martin, Mickaël, Tanaka, Yoshiya, Elhai, Muriel, Sritharan, Nanthara, Boubaya, Marouane, Balbir-Gurman, Alexandra, Siegert, Elise, Hachulla, Eric, de Vries-Bouwstra, Jeska, Riemekasten, Gabriela, Distler, Jörg H W, Rosato, Edoardo, Del Galdo, Francesco, Mendoza, Fabian A, Furst, Daniel E, de la Puente, Carlos, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Bloch-Queyrat, Coralie, and Allanore, Yannick

Published
2022
Full Text
View/download PDF

23. Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?

Author

Ghossan, Roba, Tabaa, Omar Al, Combier, Alice, Steelandt, Alexia, Thomas, Marion, Fogel, Olivier, Miceli-Richard, Corinne, Molto, Anna, Allanore, Yannick, and Avouac, Jérôme

Subjects
RHEUMATOID arthritis, VISUAL analog scale, LONG-term health care, RITUXIMAB, TREATMENT duration, RETROSPECTIVE studies, ANTIRHEUMATIC agents, TREATMENT effectiveness, MEDICAL records, ACQUISITION of data, B cells
Abstract

Objective To determine whether persistent complete B cell (BC) depletion was associated with a better clinical response in rheumatoid arthritis (RA) patients long-term treated with rituximab (RTX). Methods We conducted a retrospective study including RA patients admitted for a new infusion between 2019 and 2021. The primary endpoint was the comparison of the mean disease activity score based on 28 joints (DAS28)-CRP at each of the four last infusion visits between patients with persistent complete BC depletion (mean CD19 counts <18/µl at each of the last four visits) or without persistent complete BC depletion (mean CD19 counts of the last four visits ≥18/µl). Secondary endpoints included DAS28, pain/fatigue visual analogue scale, CRP, gammaglobulins and the frequency of self-reported RA flares. Results Of the 126 patients in maintenance therapy with RTX [exposure period: 76 (5) months, 14 (7) infusions received], 43 (34%) had persistent complete BC depletion at each of the four last infusions. The mean DAS28-CRP calculated at each of the four last infusion visits did not significantly differ according to persistence or not of complete BC depletion. This result remained unchanged after adjusting for antibody status, number of previous therapies, number of RTX infusion and cumulative RTX dose. All secondary outcomes were also not significantly different between the two groups. Conclusion Maintaining complete BC depletion does not appear to be a therapeutic target to achieve in RA patients in long-term maintenance therapy with RTX. There is a limited benefit of monitoring CD19 in RA patients long-term treated with RTX and having achieved low disease activity/remission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study.

Author

Assaraf, Morgane, Chevet, Baptiste, Wendling, Daniel, Philippe, Peggy, Cailliau, Emeline, Roux, Christian, Dieude, Philippe, Ottaviani, Sebastien, Avouac, Jérôme, Delacour, Mathilde, Houvenagel, Eric, Sellam, Jérémie, Cortet, Bernard, Henry, Julien, Flipo, René-Marc, and Devauchelle-Pensec, Valérie

Subjects
DRUG therapy, SCIENTIFIC observation, POLYMYALGIA rheumatica, RETROSPECTIVE studies, TERTIARY care, DESCRIPTIVE statistics, DRUG efficacy, RESEARCH, MEDICAL records, ACQUISITION of data, TOCILIZUMAB, CONFIDENCE intervals, DRUG tolerance, EVALUATION
Abstract

Objectives The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in patients with PMR in two recent randomized controlled trials. The objective of this multicentre retrospective study was to assess the efficacy of TCZ in PMR patients requiring glucocorticoid (GC)-sparing treatment, as well as different strategies for TCZ withdrawal. Methods We conducted a multicentre study in French tertiary healthcare departments for patients with PMR. PMR patients receiving off-label TCZ between 2015 and 2022 were included. The primary endpoint was the proportion of patients tapering to GCs ≤5 mg/day 6 months after the first TCZ infusion. The secondary endpoints were the proportion in whom GC was discontinued during follow-up, and the proportion of patients in whom TCZ was discontinued. Results Fifty-three PMR patients were included. Thirty-one patients suffered from active PMR despite conventional synthetic DMARDs. GCs were ≤5 mg/day in 77% of the patients (95% CI 36–89) at 6 months, and in 97% of the patients at 12 months. Six and 12 months after the first TCZ infusion, the proportions of GC-free patients were 22.5% (95% CI 12.7–37.8) and 58.3% (95% CI 43.2–74.1), respectively. Among TCZ withdrawal strategies, TCZ infusion spacing and TCZ dose reduction were more successful (success in 87% and 79% of attempts, respectively) than TCZ discontinuation (success in 52% of attempts; P  = 0.012 and P  = 0.039, respectively). Conclusion In GC-dependent PMR patients, treatment with TCZ led to a drastic decrease in GC dose and remission of PMR. TCZ dose reduction or TCZ infusion spacing are good options to consider in TCZ withdrawal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)

Author

Bellando-Randone, Silvia, Del Galdo, Francesco, Lepri, Gemma, Minier, Tunde, Huscher, Dörte, Furst, Daniel E, Allanore, Yannick, Distler, Oliver, Czirják, László, Bruni, Cosimo, Guiducci, Serena, Avouac, Jerome, Cutolo, Maurizio, Smith, Vanessa, and Matucci-Cerinic, Marco

Published
2021
Full Text
View/download PDF

30. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Author

Aeschlimann, Florence, Agard, Christian, Ait-Abdallah, Nassim, Albert, Jean-David, Alcais, Didier, Allain, Jean-Sébastien, Allanore, Yannick, Amador-Borreiro, Blanca, Amoura, Zahir, Andre, Emma, Arbault, Anaïs, Arlet, Jean-Benoît, Arnaud, Laurent, Arniaud, Denis, Arty-Hue, Herliette, Atlan, Lucie, Audemard-Verger, Alexandra, Audoin-Pajot, Christine, Audren, Victor, Bach-Bunner, Maxime, Bacquet-Deschryver, Hélène, Bader-Meunier, Brigitte, Balandraud, Nathalie, Balblanc, Jean-Charles, Bally, Stéphane, Banal, Frédéric, Barbery, Pierre, Barnetche, Thomas, Barrelet, Audre, Basch, André, Baumier, Vincent, Bayer, Guillaume, Bayle, Sophie, Beauvais, Catherine, Beinat, Rudie, Belin, Véronique, Belkhir, Rakiba, Benainous, Ruben, Belot, Alexandre, Benammar, Mohammed, Benhamou, Mathilde, Benhamou, Ygal, Benmansour, Ahmed, Bennet, Pascal, Bernoux-Manat, Brigitte, Berthet, Elise, Berthoux, Emilie, Bertolini, Ewa, Bigot, Adrien, Bisson-Vaivre, Aurélia, Blaison, Gilles, Bolla, Gilles, Bonidan, Olivier, Bonnet, Christine, Borie, Raphaël, Bossert, Marie, Boudou, Laurence, Bouhour, Françoise, Bouiller, Kévin, Bouldoires, Bastien, Boussoualim, Karima, Bouvard, Eric, Brondino, Regine, Buchlin, Pierre, Cabantous, Laurence, Cacoub, Patrice, Cadiou, Simon, Carteni, Maurizio, Carbasse, Aurélia, Castel, Brice, Cathebras, Pascal, Caumont, Hervé, Celant, Annalisa, Chaigne, Benjamin, Chaillous, Benoît, Champy, Romuald, Charcot, Agnès, Charles, Pierre, Charlot-Lambrecht, Isabelle, Charpin, Caroline, Chatelus, Emmanuel, Chaudier, Bernard, Chertok, Pascale, Chevalier, Xavier, Chevreau, Maxime, Chotard, Emilie, Chu Miow Lin, Delphine, Clavel, Gaëlle, Clavel-Osorio, Cyril, Cohen, Fleur, Cohen, Gregory, Colette-Cedoz, Marie-Eve, Collercandy, Nived, Colombey, Antoine, Comarmond, Chloé, Combe, Bernard, Comparon, Céline, Constant, Elodie, Coquerelle, Pascal, Corli, Justine, Corre, Clémence, Costedoat-Chalumeau, Nathalie, Couret, Marie, Courvoisier, Natacha, Coury-Lucas, Fabienne, Coutarel, Cécile, Coutier, Fabrice, Damade, Richard, Daver-Malaterre, Laurence, Dehimat, Sarahe, Delahousse, Michel, Barrois-Delattre, Emilie, Denarie, Delphine, Deprouw, Camille, Dernis, Emanuelle, Deroux, Alban, Desbarbieux, Renaud, Descamps, Elise, Deslandre, Chantal, Desmurs, Marie, Despaux, Jacques, Desplats, Marie, Detree, Frédérick, Devauchelle-Pensec, Valérie, Dhote, Robin, Dieude, Philippe, Dieudonne, Yannick, Diot, Elisabeth, Direz, Guillaume, Djeddi, Djamal-Dine, Douvier, Sarah, Drouet, Béatrice, Drumez, Elodie, Duc, Catherine, Ducornet, Angélique, Dufauret-Lombard, Carine, Duhamel, Alain, Dumaine, Cécile, Dumel, Anne-Elisabeth, Dumoulin-Richez, Chantal, Duquesne, Agnès, Durand, Géraldine, Durandin-Truffinet, Mariane, Duret, Pierre-Marie, Duval, Maïka, Ebbo, Mikaël, Ebstein, Esther, Economu-Dubosc, Andra, Emilie, Stéphanie, Euvrard, Romain, Evon, Philippe, Fabre, Sylvie, Fagedet, Dorothée, Farhat, Meryem, Fauconier, Marion, Fechtenbaum, Jacques, Felten, Renaud, Fernandes, Fanny, Ferreira-Maldent, Nicole, Feurer, Elodie, Fichet, Amandine, Flaisler, Françoise, Florens, Nans, Foltz, Violaine, Fontanges, Elisabeth, Foret, Jennifer, Fougerousse, Anne-Claire, Fouque-Aubert, Anne, Foutrier-Morello, Catherine, Francois-Pradier, Hélène, Frantzen, Léa, Fritz, Pierre, Froissart, Antoine, Fulpin, Jean, Fuzibet, Piera, Gaches, Francis, Gagneux-Lemoussu, Laurence, Penhoat-Gahier, Mélanie, Galland, Joris, Gandjbakhch, Frédérique, Garnier, Nicole, Garraud, Thomas, Garrot, Jean-François, Gastaldi, Romain, Gaud-Listrat, Véronique, Gauthier-Prieur, Maud, Georgescu, Dana, Gerard, Nathalie, Gervais, Elisabeth, Gibert, Christelle, Gibert, Eric, Gill, Ghislaine, Gillard, Jérôme, Gilson, Mélanie, Gimonnet, Pauline, Giraudet-Le Quintrec, Jeanine-Sophie, Giraud-Morelet, Aude, Glace, Baptiste, Glanowski, Camille, Godeau, Bertrand, Gombert, Bruno, Gonnet-Gracia, Camille, Goulenok, Tiphaine, Goupille, Philippe, Gourmelen, Olivier, Govindaraju-Audouard, Sophie, Grados, Franck, Grall-Lerosey, Martine, Grardel, Bruno, Grasland, Anne, Grateau, Gilles, Groza, Monica, Guillaud, Constance, Guillaume, Séverine, Guillibert, Caroline, Guillot, Xavier, Guilpain, Philippe, Gury, Aline, Guyot, Marie-Hélène, Hacquard-Bouder, Cécile, Havard, Marie-Noelle, Hellier, Jean-Pierre, Hennequin, Pascal, Henriot, Basile, Henry, Julien, Hentgen, Véronique, Hermet, Marion, Herasse, Muriel, Hernandez, Julie, Hie, Miguel, Hilliquin, Pascal, Hinschberger, Olivier, Hittinger-Roux, Ambre, Holubar, Jan, Hudry, Christophe, Huguenel, Serge, Jaccard, Clara, Jacquemier, Jean-Michel, Jamard, Bénédicte, Jan, Catherine, Jean, Sylvie, Jouvray, Mathieu, Juge, Pierre-Antoine, Juillard, Laurent, Jullien, Denis, Kabala, Anna, Kabchou, Abdelkrim, Karkowski, Ludovic, Karman, Françoise, Kemiche, Farid, Keraen, Jérémy, Kieffer, Pierre, Kone-Paut, Isabelle, Koreichi, Abdeldajallil, Kostine, Marie, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambert, Marc, Lambrecht, Isabelle, Lanot, Sylvain, Lanteri, Aurélia, Larbre, Jean-Paul, Latourte, Augustin, Lavigne, Christian, Le Guen Guegan, Sophie, Le Guenno, Guillaume, Leguy, Diane, Lebrun, Agnès, Ledoult, Emmanuel, Legoupil, Nathalie, Legrand, Erick, Lejeune, Charlotte, Leloire, Olivier, Leroux, Christophe, Leroy, Rémi, Leroy-Gouix, Marie, Leturcq, Tifenn, Leurs, Amélie, Leveque-Michaud, Céline, Limbach, François-Xavier, Liote, Frédéric, Lohse, Anne, Lozac'h, Pierre, Lucas, Virginie, Madelon, Aurélie, Magy-Bertrand, Nadine, Mahevas, Matthieu, Maillard, Hélène, Maillet, Thibault, Malochet-Guinamand, Sandrine, Mangon, Quentin, Marchou-Lopez, Sylvie, Margarit, Nathalie, Marhadour, Thierry, Mariette, Xavier, Martin, Claire, Mathian, Alexis, Maurier, François, Maury, Frédéric, Mazet-Guillaume, Betty, Mazouyez, Arnaud, Mazyad, Hassan, Mehsen-Cetre, Nadia, Meinzer, Ulrich, Melki, Isabelle, Messer, Laurent, Miceli, Corinne, Michaud, Martin, Michel, Catherine, Michel, Matthias, Michon, Mathilde, Milesi-Lecat, Anne-Marie, Molto, Anna, Moly, Marie, Moranne, Olivier, Morel, Gautier, Morel, Hugo, Morel, Jacques, Morin, Franck, Moulinier, Laurence, Moulis, Guillaume, Moura, Bertrand, Nguyen, Minh, Nicolas-Vullierme, Sabine, Nielly, Hubert, Nocturne, Gaétane, Nottez, Aurore, Ollagnon, Henri-Olivier, Pacaud-Vitoux, Isabelle, Pagnier, Anne, Paris, Caroline, Parrot, Antoine, Pascart, Tristan, Pascaud-Mansour, Yasmina, Paulin, Lætitia, Pavy, Stephan, Perard, Laurent, Pers, Yves-Marie, Pha, Micheline, Pichon, Maud, Pierreisnard, Audrey, Pizana, Gabrielle, Poignant, Sylvaine, Poix, Elsa, Portier, Agnès, Poulet, Antoine, Plassard, Samira, Pugnet, Grégory, Puyraimond-Zemmour, Déborah, Quartier-Dit-Maire, Pierre, Quenet, Marion, Queyrel, Viviane, Raffray, Loïc, Remy, Philippe, Renard, Myriam, Rene, Jessica, Revuz, Sabine, Rey, Bénédicte, Richard-Colmant, Gaëlle, Riviere, Etienne, Riviere, Sébastien, Robin, Sophie, Rohmer, Julien, Roitg, Isabelle, Romier, Mélanie, Rolland, Michel, Roriz, Mélanie, Rosenberg, Carole, Rossi, Linda, Roth, Olivier, Rouidi, Sid-Ahmed, Roumier, Mathilde, Rousiere, Mickaël, Rousselin, Clémentine, Rouviere, Bénédicte, Roux, Christian, Roux, Fabienne, Roux, Marielle, Roux, Nicolas, Rouzaud, Diane, Rozenberg, Sylvie, Sacco, Isabelle, Sadji, Fatiha, Sailler, Laurent, Salliot, Carine, Salmon, Jean-Hugues, Saraux, Alain, Schmidt, Jean, Seguier, Julie, Sellam, Jérémie, Senbel, Eric, Sene, Thomas, Senet, Patricia, Seve, Pascal, Sicaud, Aurélie, Smets, Perrine, Sobanski, Vincent, Sordet, Christelle, Sornay-Rendu, Elisabeth, Souchaud-Debouverie, Odile, Sparsa, Lætitia, Spielmann, Lionel, Steib, Sarah, Stavris, Chloé, Straus, Catherine, Strotz, Victor, Szafors, Paulina, Taffignon-Clave, Séverine, Simoens, Justine, Theillac, Claire, Tenenbaum, Nora, Thomachot, Benoît, Tieulie, Nathalie, Tiriau, Soizic, Tison, Alice, Toussirot, Eric, Trefond, Ludovic, Trijau, Sophie, Trouillier, Sébastien, Trouvin, Anne-Priscille, Truchetet, Marie-Elise, Ulrich, Marc, Vaquier, Jacques, Veillard, Eric, Veillon, Laurent, Vial, Guillaume, Viallard, Jean-François, Victor, Judith, Vidon, Claire, Vidon, Mathias, Vigne, Camille, Virone, Alexandre, Warzocha, Ursula, Wendling, Daniel, Werle, Claude, Wibaux, Cécile, Willems, Alexandra, Wisniewski, Michel, Woessner, Juliette, Xerri-Campano, Bernadette, Avouac, Jérôme, Hachulla, Eric, Seror, Raphaèle, Georgin-Lavialle, Sophie, El Mahou, Soumaya, Pertuiset, Edouard, Pham, Thao, Marotte, Hubert, Servettaz, Amélie, Domont, Fanny, Chazerain, Pascal, Devaux, Mathilde, Claudepierre, Pascal, Langlois, Vincent, Mekinian, Arsène, Maria, Alexandre Thibault Jacques, Banneville, Béatrice, Fautrel, Bruno, Pouchot, Jacques, Thomas, Thierry, Flipo, René-Marc, and Richez, Christophe

Published
2021
Full Text
View/download PDF

32. Les auteurs

Author

Bardin, Thomas, primary, Cohen-Solal, Martine, additional, Dieudé, Philippe, additional, Funck-Brentano, Thomas, additional, Lioté, Frédéric, additional, Richette, Pascal, additional, Arnaud, Laurent, additional, Ascione, Sophia, additional, Assadourian, Marina, additional, Avouac, Jérôme, additional, Beaudreuil, Johann, additional, Blandin, Camille, additional, Bourrat, Emmanuelle, additional, Bousson, Valérie, additional, Bouvard, Béatrice, additional, Chafai, Karima, additional, Chevalier, Xavier, additional, Chotard, Émilie, additional, Ea, Hang Korng, additional, Ebstein, Esther, additional, Eymard, Florent, additional, Fabre, Stéphanie, additional, Ferenczi, Antoine, additional, Forien, Marine, additional, Frazier-Mironer, Aline, additional, Gauffenic, Alan, additional, Gautier, Jean-François, additional, Guignard, Sandra, additional, Hoppé, Emmanuel, additional, Jacob, Louis, additional, Jaulerry, Sarah, additional, Juge, Pierre-Antoine, additional, Lekpa, Fernando Kemta, additional, Laloi-Michelin, Marie, additional, Laredo, Jean Denis, additional, Latourte, Augustin, additional, Léger, Bastien, additional, Legrand, Erick, additional, Miceli-Richard, Corinne, additional, Moraux, Antoine, additional, Nachef, Clément, additional, Odri, Guillaume, additional, Ottaviani, Sébastien, additional, Paccou, Julien, additional, Pham, Chinh Nghia, additional, Piat, Christophe, additional, Prati, Clément, additional, Simon, Virginie, additional, Verhoeven, Frank, additional, and Wendling, Daniel, additional

Published
2022
Full Text
View/download PDF

35. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.

Author

Thomas, Marion, Masson, Maeva, Bitoun, Samuel, Hamroun, Sabrina, Seror, Raphaele, Dupuy, Henry, Lazaro, Estibaliz, Richez, Christophe, Allanore, Yannick, and Avouac, Jérôme

Subjects
THERAPEUTIC use of monoclonal antibodies, RISK assessment, COMBINATION drug therapy, IMMUNOSUPPRESSIVE agents, SCIENTIFIC observation, SEVERITY of illness index, DESCRIPTIVE statistics, COVID-19 vaccines, PRE-exposure prophylaxis, ANTIGENS, AUTOIMMUNE diseases, DRUG efficacy, RESEARCH, CONFIDENCE intervals, TREATMENT failure, COVID-19, DISEASE incidence, COMORBIDITY, EVALUATION
Abstract

Objective To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies <260 binding antibody units/ml) in rheumatology. Methods In this multicentre observational study we included patients with autoimmune or inflammatory diseases who received pre-exposure prophylaxis with tixagevimab/cilgavimab between December 2021 and August 2022. The endpoint was incidence of COVID-19 and its severity. Results Tixagevimab/cilgavimab was administered to 115 patients with a median age of 62 years [interquartile range (IQR) 52–71], chronic arthritis (n  = 53), connective tissue disease (n  = 38) or vasculitis (n  = 11). The main background immunosuppressants were rituximab (n  = 98), corticosteroids [ n  = 62; median dose 5 mg (95% CI 5–8)] and methotrexate (n  = 48). During a median follow-up of 128 days (IQR 93–173), COVID-19 occurred in 23/115 patients (20%) and the omicron variant was identified for the eight genotyped patients. During the study period, the average weekly incidence was 1071/100 000 inhabitants in Île-de-France vs 588/100 000 in our patients. Patients who received a two-injection regimen had a lower risk of infection than those with a single injection [16/49 (33%) vs 5/64 (8%), P  = 0.0012]. The COVID-19-positive patients did not differ from uninfected patients concerning age, comorbidities, underlying rheumatic disease and immunosuppressants. All COVID-19 cases were non-severe. The tolerance of injections was excellent. Conclusion In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis withy tixagevimab/cilgavimab was associated with a lower incidence of COVID-19 and no severe infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Contribution of Rare Deleterious Variants in Telomere-Related Genes to the Risk of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis

Author

Juge, Pierre-Antoine, primary, Kawano-Dourado, Leticia, additional, Stockwell, Amy D., additional, Lee, Joyce S., additional, Ebstein, Esther, additional, Gazal, Steven, additional, McDermott, Gregory, additional, Hayashi, Keigo, additional, Cui, Jing, additional, Granger, Benjamin, additional, Kannengiesser, Caroline, additional, Borie, Raphaël, additional, Wemeau, Ludivine, additional, Debray, Marie Pierre, additional, Wolters, Paul J., additional, Marchand-Adam, Sylvain, additional, RICHEZ, Christophe, additional, Nunes, Hilario, additional, Froguel, Philippe, additional, Avouac, Jérôme, additional, Flipo, René-Marc, additional, Cottin, Vincent, additional, Boissier, Marie-Christophe, additional, Schaeverbeke, Thierry, additional, Kermanac’h, Nathalie Saidenberg, additional, Crestani, Bruno, additional, Doyle, Tracy, additional, Raychaudhuri, Soumya, additional, Karlson, Elizabeth W., additional, Yaspan, Brian L., additional, Sparks, Jeffrey A., additional, and Dieudé, Philippe, additional

Published
2024
Full Text
View/download PDF

43. Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.

Author

Faganello, Déborah, Bertrand, Anne, Meunier, Pauline, Avouac, Jérôme, Toussirot, Eric, Coury, Fabienne, Seror, Raphaele, Mélédo, Guillaume Le, Germain, Vincent, Dellal, Azedinne, Shima, Ditmar, Hulin, Cyrille, Prati, Clément, Schaeverbeke, Thierry, Richez, Christophe, Truchetet, Marie-Elise, and Kostine, Marie

Subjects
DRUG therapy for rheumatism, RHEUMATOID arthritis diagnosis, REPORTING of diseases, PATIENT aftercare, PROTEINS, JANUS kinases, MONOCLONAL gammopathies, CONTENT mining, DESCRIPTIVE statistics, RESEARCH funding, NEUROTRANSMITTER uptake inhibitors, PHARMACODYNAMICS
Abstract

Objective Monoclonal gammopathy of undetermined significance (MGUS) is common, but there are scarce data regarding the effect of DMARDs on this premalignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKis) on MGUS when initiated for an active rheumatic disease. Methods Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease were identified through the MAJIK-SFR Registry, a French multicentre prospective study. Clinical and biological data were collected using a standardized case report form. Results Twenty patients were identified with a mean age of 65 years and a diagnosis of RA (n  = 15), PsA (n  = 3), and axial SpA (n  = 2). The JAKi prescribed was baricitinib (n  = 9), tofacitinib (n  = 6) or upadacitinib (n  = 5), with a mean duration of 15.5 months. Seventeen patients had individualized serum monoclonal protein (IgG kappa n  = 9; IgG lambda n  = 4; IgM kappa n  = 3; IgA lambda n  = 1) ranging from 0.16 to 2.3 g/dl, and three patients did not have an initial measurable spike but they had a positive serum immunofixation. With a follow-up of 4–28 months, the serum monoclonal protein level decreased in 8 of 17 patients (47%), remained stable in 8 patients (47%) and increased in 1 patient (6%). The maximal decrease observed was an initial IgG kappa of 2.3 g/dl, decreasing to 0.2 g/dl at month 14. Conclusion This study provides reassuring and promising data on MGUS evolution in patients treated with JAKis for rheumatic diseases, which may guide the choice of treatment in patients with both conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. DAS28-γGT for the prediction of major cardiovascular events in rheumatoid arthritis: results from the ESPOIR cohort.

Author

Dupont, Anne, Constantin, Arnaud, Soubrier, Martin, Rincheval, Nathalie, and Avouac, Jérôme

Subjects
GAMMA-glutamyltransferase, PREDICTIVE tests, CONFIDENCE intervals, MAJOR adverse cardiovascular events, MULTIVARIATE analysis, AGE distribution, SEVERITY of illness index, RISK assessment, RHEUMATOID arthritis, SYMPTOMS, PREDICTION models, RECEIVER operating characteristic curves, SENSITIVITY & specificity (Statistics), LONGITUDINAL method, PROPORTIONAL hazards models, DISEASE risk factors, DISEASE complications, EVALUATION
Abstract

Objective To validate the predictive value of the DAS28 γ-glutamyl transferase (DAS28-γGT) for the occurrence of major cardiovascular (CV) events (MACE) in the 'Etude et Suivi des Polyarthrites Indifférenciées Récentes' ESPOIR cohort. Methods Analysis of 13-year outcome from the ESPOIR cohort. RA patients with missing data for baseline γGT activity and those not followed-up to 1 year were excluded. Baseline DAS28-γGT was calculated using the following formula: 0.56*√TJ-28 + 0.28 * √SJ-28 + 2*ln(γGT) + 0.014 * GH. Our primary outcome was the merit of the DAS28-γGT in predicting the occurrence of MACE. Results Among the 696 patients [536 women, mean (s. d.) age of 49 (12) years], 34 MACE were recorded, with a mean time to event of 71 (44) months. Receiver operating characteristic curve analysis indicated that a DAS28-γGT >9.4 had the best sensitivity and specificity for the diagnosis of MACE during the observation period. DAS28-γGT >9.4 was predictive of the occurrence of MACE, with a hazard ratio (HR) of 3.11 (95% CI 1.41, 5.43). Multivariate Cox analyses confirmed higher DAS28-γGT (HR 2.44, 95% CI 1.05, 5.64) together with age (HR 1.04, 95% CI 1.01, 1.07) and diabetes mellitus (HR 4.12, 95% CI 1.55, 10.95) as independent predictors of MACE. There was a dose effect of the DAS28-γGT for MACE-risk prediction, which was in line with the application of the Framingham risk score. Conclusion The DAS28-γGT was identified in this large prospective cohort as an independent predictor of MACE in patients with RA. The DAS28-γGT is a simple and useful tool to evaluate CV risk in routine and warn the clinician about the CV risk burden in patients with RA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Effects of B Cell Depletion by CD19-Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis.

Author

Avouac, Jérôme, Cauvet, Anne, Orvain, Cindy, Boulch, Morgane, Tilotta, Françoise, Ly Tu, Thuillet, Raphaël, Ottaviani, Mina, Guignabert, Christophe, Bousso, Philippe, and Allanore, Yannick

Subjects
*INFLAMMATION prevention, *ANIMAL experimentation, *SYSTEMIC scleroderma, *CELL receptors, *MONOCLONAL antibodies, *TREATMENT effectiveness, *T cells, *PULMONARY fibrosis, *ANTIGENS, *MICE, *VASCULAR remodeling
Abstract

Objective. Our goal was to study the tolerance and efficacy of two B cell depletion strategies, including one with CD19-targeted chimeric antigen receptor (CAR) T cells, in a preclinical model mimicking the severe lung damages observed in systemic sclerosis. Methods. B cell depletion strategies were evaluated in the Fra-2 transgenic (Tg) mouse model. We considered a first group of 16 untreated mice, a second group of 15 mice receiving a single dose of anti-CD20 monoclonal antibody (mAb), and a third group of 8 mice receiving CD19-targeted CAR-T cells in combination with anti-CD20 monoclonal antibody. After six weeks of clinical evaluation, different validated markers of inflammation, lung fibrosis, and pulmonary vascular remodeling were assessed. Results. CD19-targeted CAR-T cells infusion in combination with anti-CD20 mAb resulted in a deeper B cell depletion than anti-CD20 mAb alone in the peripheral blood and lesional lungs of Fra-2 Tg mice. CAR-T cell infusion worsened the clinical score and increased mortality in Fra-2 Tg mice. In line with the above findings, CAR-T cell infusion significantly increased lung collagen content, the histological fibrosis score, and right ventricular systolic pressure. CAR-T cells accumulated in lesional lungs and promoted T activation and inflammatory cytokine production. Treatment with anti-CD20 mAb in monotherapy had no impact on lung inflammation–driven fibrosis and pulmonary hypertension. Conclusion. B cell therapies failed to show efficacy in the Fra2 Tg mice. The exacerbated Fra-2 lung inflammatory burden stimulated accumulation and expansion of activated CD19-targeted CAR-T cells, secondarily inducing T cell activation and systemic inflammation, finally leading to disease worsening. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Comparing COVID-19 disease severity in patients with rheumatic and inflammatory diseases between the first and the subsequent waves

Author

Drumez, Elodie, primary, Richez, Christophe, additional, Bebear, Louis, additional, Herasse, Muriel, additional, Flipo, René-Marc, additional, Marotte, Hubert, additional, Georgin-Lavialle, Sophie, additional, Seror, Raphaèle, additional, Pertuiset, Edouard, additional, Avouac, Jérôme, additional, Chazerain, Pascal, additional, Roux, Nicolas, additional, Pham, Thao, additional, Dernis, Emmanuelle, additional, Uzunhan, Yurdagul, additional, Servettaz, Amélie, additional, El Mahou, Soumaya, additional, Cacoub, Patrice, additional, Hamidou, Mohamed, additional, Fautrel, Bruno, additional, Thomas, Thierry, additional, and Hachulla, Eric, additional

Published
2023
Full Text
View/download PDF

49. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicenter retrospective observational study

Author

Assaraf, Morgane, primary, Chevet, Baptiste, additional, Wendling, Daniel, additional, Philippe, Peggy, additional, Cailliau, Emeline, additional, Roux, Christian, additional, Avouac, Jérôme, additional, Delacour, Mathilde, additional, Houvenagel, Eric, additional, Sellam, Jérémie, additional, Cortet, Bernard, additional, Henry, Julien, additional, Flipo, René Marc, additional, and Devauchelle-Pensec, Valérie, additional

Published
2023
Full Text
View/download PDF

50. Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry

Author

Faganello, Déborah, primary, Bertrand, Anne, additional, Meunier, Pauline, additional, Avouac, Jérôme, additional, Toussirot, Eric, additional, Coury, Fabienne, additional, Seror, Raphaele, additional, Le Mélédo, Guillaume, additional, Germain, Vincent, additional, Dellal, Azedinne, additional, Shima, Ditmar, additional, Hulin, Cyrille, additional, Prati, Clément, additional, Schaeverbeke, Thierry, additional, Richez, Christophe, additional, Truchetet, Marie-Elise, additional, and Kostine, Marie, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results